



ALG-2 knockdown in HeLa cells results in G2/M cell cycle phase accumulation and cell death

Berit R. Høj, Jonas M. la Cour, Jens Møllerup, Martin W. Berchtold *

Copenhagen Biocenter, Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark

ARTICLE INFO

Article history:

Received 3 November 2008

Available online 14 November 2008

Keywords:

Calcium-binding proteins

Apoptosis-linked gene-2 (ALG-2)

siRNA

Apoptosis

Cell cycle

Caspase

ABSTRACT

ALG-2 (apoptosis-linked gene-2 encoded protein) has been shown to be upregulated in a variety of human tumors questioning its previously assumed pro-apoptotic function. The aim of the present study was to obtain insights into the role of ALG-2 in human cancer cells. We show that ALG-2 downregulation induces accumulation of HeLa cells in the G2/M cell cycle phase and increases the amount of early apoptotic and dead cells. Caspase inhibition by the pan-caspase inhibitor zVAD-fmk attenuated the increase in the amount of dead cells following ALG-2 downregulation. Thus, our results indicate that ALG-2 has an anti-apoptotic function in HeLa cells by facilitating the passage through checkpoints in the G2/M cell cycle phase.

© 2008 Elsevier Inc. All rights reserved.

The calcium-binding protein ALG-2 was initially identified as a factor needed for TCR mediated apoptosis in 3DO mouse cells [1]. Since ALG-2 binds calcium at the micromolar (μM) level [2], it has been proposed that ALG-2 could be involved in calcium mediated signaling processes regulating cell death (reviewed in [3,4]). Induction of cell death by various means was partially impaired in the ALG-2 depleted 3DO clones [1,4] and it was proposed that ALG-2 has a pro-apoptotic function in the murine Apaf^{-/-} cell line [5]. In addition, it was shown that the death-inducing effect of Alix (apoptosis-linked gene-2 (ALG-2)-interacting protein X) on chicken neuroepithelial cells is dependent on its ability to bind ALG-2 [6]. However, the pro-apoptotic function of ALG-2 has not been confirmed in human cells. Recent findings that ALG-2 is overexpressed in a variety of human tumors [7–10] and that ALG-2 may contribute to cancer cell viability [9] challenge the concept that ALG-2 is a general pro-apoptotic factor. The present study provides evidence that ALG-2 depleted HeLa cells accumulate in the G2/M phase of the cell cycle and that depletion of ALG-2 increases the fraction of early apoptotic and dead cells.

Materials and methods

Cell lines and siRNA transfection. The human cervical carcinoma cell line, HeLa, was grown as earlier described [11]. A day prior to siRNA transfection the cells ($10,400 \text{ cells}/\text{cm}^2$) were seeded in medium

containing 10% FBS. Cells were transiently transfected with 50 nM siRNA using Oligofectamine reagent (Invitrogen) according to the manufacturer's transfection protocol. For investigations of cell viability/apoptosis the cells were reseeded the following day for a second round of siRNA transfection. The previously described ALG-2 siRNA (siALG-2) duplexes targeting position 112–130 and 197–215 of the ALG-2 transcript (GenBank Accession No. NM_013232) [9] were used to achieve ALG-2 downregulation and the siRNA against the firefly luciferase gene (siGL2) was included as a non-targeting control [12]. All siRNA duplex oligonucleotides were obtained from Dharmacon (Lafayette, CO, USA).

Western blot analysis. Following trypsinization cells were harvested with spent medium to include nonadherent cells. Cells were washed with PBS and extracts were prepared in lysis buffer and further processed for Western blotting as described [9]. The polyclonal anti-ALG-2 antibodies were purified in our laboratory [8] and monoclonal mouse anti-cyclin B1 and polyclonal goat anti-Hsc70 antibodies were from Santa Cruz Biotechnology (Santa Cruz). Secondary HRP conjugated antibodies (Goat anti-rabbit, goat anti-mouse and rabbit anti-goat) were obtained from Dako. As loading controls immunoblotting using Hsc70 antibodies were used.

Cell cycle profile. Adherent and nonadherent cells were collected and a subset of the cells were isolated for Western blot analysis of ALG-2, cyclin B1, and Hsc70 content. The remaining cells were washed once and resuspended in cold PBS containing 1% FBS (PBS/FBS). The cells were fixed and permeabilized by adding ice-cold ethanol to a final concentration of 84% followed by incubation at 4 °C for at least 30 min. DNA staining was done by resuspending approximately $1 \times 10^6 \text{ cells}/\text{ml}$ in PBS/FBS containing 50 $\mu\text{g}/\text{ml}$

* Corresponding author. Fax: +45 35322128.

E-mail address: mabe@bio.ku.dk (M.W. Berchtold).

propidium iodide (PI; Sigma–Aldrich), 10 µg/ml RNase-A (Sigma–Aldrich) and incubated for 30 min at 37 °C. Samples were kept in dark on ice until analysis by flow cytometry (FACScan; BD Biosciences, Franklin Lakes, NJ, USA). The distribution of cells in the cell cycle was analysed using the ModFit LT software (BD Biosciences).

Annexin V assay. Detached cells were collected and attached cells were briefly trypsinized. The cells were pooled, washed once in PBS and resuspended to approximately 1×10^6 cells/ml in a buffer containing 0.01 M HEPES–NaOH, pH 7.4; 140 mM NaCl; 2.5 mM CaCl_2 . The cells were stained by incubation for 15 min with 2% v/v fluorescein isothiocyanate (FITC)-conjugated Annexin V (ANNEX-INV01, Invitrogen) and 8.0 µg/ml 7-amino-actinomycin (7-AAD; Sigma–Aldrich) at room temperature. Samples were kept in the dark on ice until analysed by flow cytometry on a BD FACScan. The populations of viable (Annexin V-FITC negative; 7-AAD negative), early apoptotic (Annexin V-FITC positive; 7-AAD negative) and dead (7-AAD positive) cells were determined using the Summit software (Dako, Glostrup, Denmark) [13].

Caspase inhibition. Twenty-four hours following siRNA transfection 25 or 50 µM of the pan-caspase inhibitor z-VAD-fmk (Bachem) was added and the cells were incubated for 48 h in the presence of inhibitor. The fractions of early apoptotic and dead cells were determined using the Annexin V assay.

Statistical analysis. Statistical analysis was performed using the Student's *t*-test. A *p* value less than 0.05 was considered significant.

Results

ALG-2 deficiency leads to G2/M cell cycle phase accumulation

Previous investigations showed that knockdown of ALG-2 in HeLa and U2OS cells resulted in a decreased proliferation rate of cells [9]. This could indicate that they were arrested in a specific

cell cycle phase or progressed more slowly through the entire cell cycle. To address this question two different siRNAs against the ALG-2 transcript were used (siALG-2 112 and siALG-2 197) to downregulate ALG-2 expression [9]. Cells, either non-transfected or transfected with 50 nM siGL2, siALG-2 112 or siALG-2 197, were analysed by FACS three days following siRNA transfection. A decrease in the 2N and an increase in the 4N DNA content was observed (Fig. 1A) following partial downregulation of ALG-2 (Fig. 1B). Compared to control siGL2 transfected cells a significant increase in the G2/M (4N) population of 51% was observed following partial ALG-2 knockdown using siALG-2 112 and 197, respectively (Fig. 1C). To further examine whether partial knockdown of ALG-2 resulted in G2/M arrest, the protein level of a known G2/M cell cycle phase marker, cyclin B1 [14], was examined by Western blot analysis. Immunoblotting of lysates from cells harvested from the same cultures as used for FACS analysis showed elevated levels of cyclin B1 (Fig. 1B) supporting our FACS analysis studies, which point to a G2/M phase arrest as a result of partial ALG-2 downregulation. Cyclin B1 levels were 5- and 3.5-fold higher in the siALG-2 112 and 197 transfected cells, respectively as compared to the cyclin B1 levels in siGL2 transfected cells (Fig. 1D).

ALG-2 downregulation leads to induction of caspase dependent cell death pathways

In order to evaluate the effect of ALG-2 downregulation on cell viability, the exposure of phosphatidylserine on the outer cell membrane (Annexin V staining), and cell permeability (7-AAD staining) were examined by flow cytometry. Partial depletion of ALG-2 led to a marked increase in the number of early apoptotic and dead cells as compared to non-transfected or control (siGL2) transfected cells (Fig. 2). Comparing single and double siRNA transfected cells it was clear that more early apoptotic cells were pres-




Fig. 1. Downregulation of ALG-2 increases the population of cells in the G2/M phase of the cell cycle. (A) Representative histograms showing the cell cycle profile of siGL2 and siALG-2 112 transfected cells. (B) Western blot analysis of ALG-2, cyclin B1, and Hsc70 levels in siRNA transfected cells. (C) Cell cycle phase distribution of cells relative to siGL2 transfected cells. Data represent the mean of three independent experiments and bars indicate standard error of the mean. (D) Quantification in arbitrary units (AU) of cyclin B1 levels relative to the loading control, Hsc70. Measurements were done on three independent experiments. Error bars indicate standard error of the mean. Asterisks indicate *t*-test *p*-values less than 0.05 when the results obtained with the ALG-2 siRNAs were compared with those obtained with the siGL2 control RNA. Increase in the G2/M population, *p* = 0.003 and 0.04; increase in cyclin B1 level, *p* = 0.03 and 0.016 for siALG-2 112 and 197, respectively.

Download English Version:

<https://daneshyari.com/en/article/1934738>

Download Persian Version:

<https://daneshyari.com/article/1934738>

[Daneshyari.com](https://daneshyari.com)